Assessment of Long‐Term Use Versus Discontinuation of Direct Oral Anticoagulant After Catheter Ablation for Atrial Fibrillation—RYOUMA Registry Subanalysis

Assessment of Long‐Term Use Versus Discontinuation of Direct Oral Anticoagulant After Catheter Ablation for Atrial Fibrillation—RYOUMA Registry Subanalysis

ABSTRACT Background The relationship between oral anticoagulant (OAC) status after catheter ablation (CA) for atrial fibrillation (AF) and the risks of ischemic stroke or major bleeding events is still unknown. Methods This is a subanalysis of the RYOUMA registry, a prospective multicenter observati...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuka Oda, Akihiko Nogami, Yuki Komatsu, Kyoko Soejima, Itsuro Morishima, Kenichi Hiroshima, Ritsushi Kato, Satoru Sakagami, Fumiharu Miura, Keisuke Okawa, Masayuki Fukuzawa, Atsushi Takita, Kikuya Uno, Koichiro Kumagai, Takashi Kurita, Masahiko Gosho, Tomoko Ishizu, Kazutaka Aonuma, the RYOUMA Investigators
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Annals of Noninvasive Electrocardiology
Subjects:
anticoagulation
atrial fibrillation
catheter ablation
hemorrhage
stroke
Online Access:https://doi.org/10.1111/anec.70067
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background The relationship between oral anticoagulant (OAC) status after catheter ablation (CA) for atrial fibrillation (AF) and the risks of ischemic stroke or major bleeding events is still unknown. Methods This is a subanalysis of the RYOUMA registry, a prospective multicenter observational study of Japanese patients who underwent CA for AF in 2017–2018. Results Of the 2844 patients, the rate of DOAC continuation was 48.1%, 69.6%, and 80.9% in patients with a CHADS2 score of 0–1, 2, and 3–6, respectively. Among the patients taking DOACs with a CHADS2 score of 0–1 and 2, the incidence rates of major bleeding were significantly higher than those of ischemic stroke or systemic embolic events (SEEs) (1.3%/year [95% CI, 0.6–2.1] vs. 0.3%/year [95% CI, 0.0–0.7], p = 0.019; 1.8%/year [95% CI, 0.6–3.0] vs. 0.2%/year [95% CI, 0.0–0.6], p = 0.018, respectively). However, there was no difference between the incidence rates of major bleeding events and ischemic stroke or SEEs in patients taking DOACs with a CHADS2 score of 3–6 (1.6%/year [95% CI, 0.2–3.0] vs. 1.0%/year [95% CI, 0.0–2.1], p = 0.474). Conclusions In patients with a CHADS2 score of 2, those who continued taking DOACs had a higher incidence rate of major bleeding events compared to ischemic stroke/SEEs, similar to those with a CHADS2 score of 0–1. Conversely, in patients with a CHADS2 score of 3–6, the incidence rates of both ischemic stroke/SEEs and major bleeding were similarly high. Trial Registration: The study was registered as UMIN000026092 (University Hospital Medical Information Network‐Clinical Trial Registry)
ISSN:1082-720X
1542-474X

Similar Items